Faeth Therapeutics, Inc（FTH）资讯与事件FTHFaeth Therapeutics, Inc

Faeth Therapeutics Appoints Dr. Karen Vousden to Board of Directors

Faeth Therapeutics "announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026. Dr. Vousden is a cancer biologist recognized for her work on the regulation and function of the p53 tumor suppressor protein and on the metabolic dependencies of tumors. She has served as a Principal Group Leader at The Francis Crick Institute in London since 2017. She was Chief Scientist of Cancer Research UK from 2016 to 2022 and Director of the Beatson Institute for Cancer Research from 2002 to 2016. Dr. Vousden has served on the board of directors of Bristol Myers Squibb Company since 2018, where she is a member of the Science and Technology Committee and the Compensation and Management Development Committee. She is a Fellow of the Royal Society, the Royal Society of Edinburgh, the Academy of Medical Sciences, EMBO, the European Academy of Sciences, the American Association for Cancer Research and the American Academy of Arts and Sciences, and a Foreign Associate of the U.S. National Academy of Sciences. Dr. Vousden received her Ph.D. in genetics from Queen Mary College at the University of London. She is a scientific co-founder of Faeth."

Faeth Therapeutics Grants 94,000 Stock Options to New Employees

Faeth Therapeutics announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Company's common stock in connection with their employment. The Option Awards were granted effective August 25, 2026, pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment with Faeth in accordance with Nasdaq Listing Rule 5635(c)(4).

Faeth Therapeutics Completes Merger with Sensei Biotherapeutics, Secures $200 Million Financing

"Our combination with Sensei Biotherapeutics marked an important milestone in the history of Faeth Therapeutics," said Anand Parikh, Chief Executive Officer. "With the concurrent $200 million PIPE financing, we now have the capital to interrogate the multi-nodal hypothesis in multiple cancers. We look forward to reading out topline data from our Phase 2 PIK-201 trial in endometrial cancer, which is expected by year-end."